Key insights
- INVO Fertility (IVF) is implementing a 1-for-5 reverse stock split. This action typically signals financial distress or an attempt to regain Nasdaq compliance, potentially leading to short-term negative sentiment for the stock. However, the long-term impact on the broader US equity market is minimal.
INVO Fertility Inc. (IVF) will implement a 1-for-5 reverse stock split of its common stock effective at 12:01 a.m. Eastern Time on March 27, 2026. The company’s shares will continue trading on the Nasdaq Capital Market under the same symbol "IVF" starting with the market opening that day.
Under the reverse split, every five shares of outstanding common stock will be consolidated into one share. The new CUSIP number for the company’s common stock will be 44984F880. Registered shareholders who would hold fractional shares will be rounded up to the next whole share, while beneficial holders with fractional shares through brokers will receive cash payments determined by their brokers.
Following the reverse split, INVO Fertility will have approximately 1,615,419 shares of common stock outstanding. The company’s authorized shares will be proportionally adjusted to 50,000,000 shares of authorized common stock.
INVO Fertility operates as a healthcare services company in the fertility market. The company builds, acquires and operates fertility clinics, including facilities dedicated to its intravaginal culture procedure using the INVOcell medical device. The company currently operates four fertility clinics in the United States and distributes its INVOcell technology to third-party fertility clinics.
The information is based on a company press release statement.